Weight-Loss Drugmakers Hit with Antitrust Lawsuit, Trump’s Plan Brings Down Energy Stocks

🎙️ The Voices & The Context

• The Format: Solo-narrated daily market update podcast, structured as a fast-paced rundown of news, headlines, stock moves, and teases for future episodes—in under 10 minutes.
• The Key Players: Host Admonty, a market commentator who delivers energetic updates; no guests today, but teases an upcoming interview with Bloomberg reporter Ashley Carmen on Netflix's podcast push.
• The Vibe: Energetic and educational with a fun, conversational edge—quick hits of market drama, personal anecdotes, and "fun facts" keep it lively despite dense financial info.

🗝️ Key Themes & Topics

Four punchy segments drive the episode: market volatility amid big rulings, pharma battles over weight-loss drugs, streaming giant expansions, and Wall Street paradoxes.

• Market Recap & Supreme Court Tariffs: Markets rebounded slightly (S&P 500 +0.3%, Nasdaq +0.2%) after losses, but eyes on Supreme Court ruling on Trump's tariffs under the International Emergency Economic Powers Act—could spark refunds and volatility; teases big tech earnings and Fed-Trump tensions.
• GLP-1 Pharma Lawsuit: Eli Lilly and Novo Nordisk sued by compounding pharmacy Strive Specialties for allegedly blocking low-cost copycats; gray area around shortages and patient-specific doses amid patent expirations (e.g., Novo Nordisk's semaglutide soon outside US).
• **Netfli